622 related articles for article (PubMed ID: 27492436)
1. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
Trejo P; Rauch F
Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta: diagnosis and treatment.
Palomo T; Vilaça T; Lazaretti-Castro M
Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):381-388. PubMed ID: 28863000
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
4. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
5. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
7. [Oesteogenesis imperfecta--genetics, diagnosis and medical treatment].
Brixen KT; Illum NO; Hansen B; Lund AM; Mosekilde L
Ugeskr Laeger; 2007 Jan; 169(1):30-4. PubMed ID: 17217883
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations.
Pollitt RC; Saraff V; Dalton A; Webb EA; Shaw NJ; Sobey GJ; Mughal MZ; Hobson E; Ali F; Bishop NJ; Arundel P; Högler W; Balasubramanian M
Am J Med Genet A; 2016 Dec; 170(12):3150-3156. PubMed ID: 27576954
[TBL] [Abstract][Full Text] [Related]
10. Update on the evaluation and treatment of osteogenesis imperfecta.
Harrington J; Sochett E; Howard A
Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022
[TBL] [Abstract][Full Text] [Related]
11. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
13. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
Trejo P; Fassier F; Glorieux FH; Rauch F
J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
[TBL] [Abstract][Full Text] [Related]
14. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
15. Clinical, genetic characteristics and treatment outcomes of children and adolescents with osteogenesis imperfecta: a two-center experience.
Erbaş İM; İlgün Gürel D; Manav Kabayeğit Z; Koç A; Ünüvar T; Abacı A; Böber E; Anık A
Connect Tissue Res; 2022 Jul; 63(4):349-358. PubMed ID: 34107839
[TBL] [Abstract][Full Text] [Related]
16. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
17. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum.
Bardai G; Moffatt P; Glorieux FH; Rauch F
Osteoporos Int; 2016 Dec; 27(12):3607-3613. PubMed ID: 27509835
[TBL] [Abstract][Full Text] [Related]
18. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
[TBL] [Abstract][Full Text] [Related]
19. Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype.
Cundy T; Dray M; Delahunt J; Hald JD; Langdahl B; Li C; Szybowska M; Mohammed S; Duncan EL; McInerney-Leo AM; Wheeler PG; Roschger P; Klaushofer K; Rai J; Weis M; Eyre D; Schwarze U; Byers PH
J Bone Miner Res; 2018 Jul; 33(7):1260-1271. PubMed ID: 29669177
[TBL] [Abstract][Full Text] [Related]
20. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
